The Partnering Agreements with Ranbaxy report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
Ranbaxy Laboratories is a top pharmaceutical company based in Haryana, India
Ranbaxy is a research based pharmaceutical company with a strong focus on developing generics.
Indian pharma major Ranbaxy is likely to announce a tie-up with a multinational company for sourcing active pharmaceutical ingredient (API) for its blood pressure drug- Diovan.
By Steve Poile With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.
The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango
Sun Pharmaceutical has announced 6 M&A deals since 2009.
Sorry, your search returned no results.
Mumbai, India: March 25, 2015 – Sun Pharmaceutical Industries Ltd., begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
U.S. buyout firm KKR & Co LP has agreed to invest about $200 million in Indian drugmaker Gland Pharma Ltd, marking the largest private equity investment in the local pharmaceutical sector amid growing demand for generic drugs in overseas markets.
Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.